UK: Speedy Drafting Or Drafting For Priority?

Last Updated: 3 February 2014
Article by Daniel Rowe

Lessons from the Court of Appeal in Hospira & Mylan vs Novartis ([2013] EWCA Civ 1663)

The Court of Appeal has recently handed down a decision focusing on issues of priority and the extent to which isolated disclosures in the detailed description of an earlier application of all of the features a later claim may support the right to priority for that claim.  Specifically considered was the teaching that can be derived from a simple statement of a preferred dosage range for a pharmaceutical. This decision can be viewed as a general lesson for the drafting of all effective priority documents in Europe and specific guidance on how European courts construe certain disclosures of dosage ranges.  With dosage regimes emerging as an area of patentable new invention and becoming more and more relevant commercially as personalised medicine fast becomes a reality, this guidance is timely.

The single claim under consideration claimed the use of a zoledronate medicine for the treatment of osteoporosis where the medicine is adapted for intravenous administration in a unit dosage form which comprises from about 2 up to about 10mg of zoledronate, wherein the period between administrations is about once a year.  The priority filing referred to all of these features at some point in its text, and even one or two in combination with some of the others, but the complete combination of the claim was not.  Notably, the dosage range was not disclosed in connection with the specific route of administration (intravenous) or with the specific medical indication (osteoporosis).  Novartis' case was, however, that the text of the priority filing should be read as a whole and, when it is, the link between the various features of the claim can be seen to run through the entire document. 

The Court made reference to the relevant law on priority at the EPO and in the UK (Art. 87 and 88 EPC and Section 5 of the UK Patents Act 1977) and reaffirmed that, although the language differs, the two provisions must be taken to mean the same thing, i.e. that priority can only be acknowledged if the skilled person can derive the subject-matter of the claims directly and unambiguously, using common general knowledge, from the previous application as a whole.  The Court cautioned against the practice of simply tracing the sources of a plurality of claim features in a previous application and not considering their interplay with the other features of the claim or the context in which they are found.

In reaching its decision the Court relied on expert evidence to construe a disclosure which teaches a dosage regime of 2 up to about 10mg of zoledronate about once a year, but which does not teach a specific route of administration for such a regime or the specific medical indications that are treated by that regime.  Since the application as a whole referred in general to the treatment of conditions associated with abnormally increased bone turnover via a number of differing administration routes, on the balance of this expert evidence, the Court decided that the skilled man would understand this teaching to amount to that of a range of doses that would be suitable to cover the use of zoledronate in the treatment of the many conditions associated with abnormally increased bone turnover via any route of administration, with some routes/conditions requiring dosages at the lower end, others at the upper end, and many in between.  As a result, in the absence of being informed otherwise, the skilled man would not have taken the disclosure of this dosage range as a preferred dosage range for the treatment of osteoporosis via intravenous administration (even though it was clear from the application as a whole that osteoporosis was a preferred target disease and intravenous administration was a notable route of administration). The specific combination of this dosage range with the teaching of intravenous administration and the treatment of osteoporosis was therefore not a combination that was directly and unambiguously derivable from the priority document and the claim was not entitled to priority.

This decision emphasises the dangers in succumbing to the temptation of corner-cutting at the priority filing stage.  Specifically in the context of pharmaceutical therapies, a detailed description filled with boiler plate dosage ranges might not provide adequate support for future claims to the use of such ranges in specific treatment contexts.  If the inventive concept is likely to lie in the use of specific dosage regimes to treat specific medical indications, the draftsman must take the time to consider which doses can be used in which treatment contexts and make sure his disclosure includes such specific combinations of dose, condition to be treated and administration route.  

This decision also serves as a reminder to those beyond the pharmaceutical field of how strictly priority provisions are applied in Europe and how a "planting the flag" approach to a priority filing may well result in a priority application that will be unable to provide sufficient support in Europe for later claims more specific embodiments/combinations.  Applicants would be well advised to resist the temptation to cut costs at this crucial stage of an application by filing a cursory description of their invention and instead plan to invest time and money in drafting a full application, ideally engaging the services of an experienced European Patent Attorney. 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.